Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

PAD2 overexpression in transgenic mice augments malignancy and tumor-associated inflammation in chemically initiated skin tumors

  • 484 Accesses

  • 1 Citations

Abstract

We previously found that transgenic mice overexpressing MMTV-FLAG-hPAD2 (PAD2OE) developed spontaneous skin lesions, with a subset of these lesions progressing to invasive squamous cell carcinoma (SCC). The goal of this report was to better understand the potential mechanisms by which PAD2 overexpression promotes skin cancer. Here, PAD2OE mice were treated with the carcinogen, 9,10-dimethyl-1,2-benzanthracene and with O-tetradecanoylphorbol-13-acetate and then scored for papilloma formation. Additionally, tumor sections were evaluated for evidence of tumor cell invasion and inflammation. We found that the total number of papillomas was significantly increased in PAD2OE mice compared to controls. Histopathologic analysis of the lesions found that in PAD2OE skin tumors progressed to invasive SCC more frequently than controls. Additionally, we found that PAD2OE lesions were highly inflamed, with a dense inflammatory cell infiltrate and an associated increase in nuclear phospho-STAT3 (signal transducer and activator of transcription 3) in the transgenic tumors. These data suggest that overexpression of the hPAD2 transgene in the epidermis increases the malignant conversion rate of benign tumors by promoting an inflammatory microenvironment.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Bhatia A, Singh B, Raza K, Shukla A, Amarji B, Katare OP (2012) Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis. J Drug Target 20:544–550

  2. Burns FJ, Vanderlaan M, Sivak A, Albert RE (1976) Regression kinetics of mouse skin papillomas. Cancer Res 36:1422–1427

  3. Cherrington BD, Morency E, Struble AM, Coonrod SA, Wakshlag JJ (2010) Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones. PLoS ONE 5:e11768

  4. Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, Davis T, Matesic LE, Thompson PR, Hofseth LJ (2011) Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol 300:G929–G938

  5. Filler RB, Roberts SJ,Girardi M (2007) Cutaneous two-stage chemical carcinogenesis. CSH Protoc 2007:pdb prot4837

  6. Fujiki H, Suganuma M, Suguri H, Yoshizawa S, Hirota M, Takagi K, Sugimura T (1989b) Diversity in the chemical nature and mechanism of response to tumor promoters. Prog Clin Biol Res 298:281–291

  7. Fujiki H, Suganuma M, Yoshizawa S, Kanazawa H, Sugimura T, Manam S, Kahn SM, Jiang W, Hoshina S, Weinstein IB (1989a) Codon 61 mutations in the c-Harvey-ras gene in mouse skin tumors induced by 7,12-dimethylbenz[a]anthracene plus okadaic acid class tumor promoters. Mol Carcinog 2:184–187

  8. Hennighausen L, Wall RJ, Tillmann U, Li M, Furth PA (1995) Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J Cell Biochem 59:463–472

  9. Hennings H, Glick AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH (1993) FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14:2353–2358

  10. Horibata S, Coonrod SA, Cherrington BD (2012) Role for peptidylarginine deiminase enzymes in disease and female reproduction. J Reprod Dev 58:274–282

  11. Kim MO, Kim SH, Shin MJ, Yu DH, Kim BS, Chang KT, Lee S, Park YB, Lee TH, Ryoo ZY (2007) DMBA/TPA-induced tumor formation is aggravated in human papillomavirus type 16 E6/E7 transgenic mouse skin. Oncol Res 16:325–332

  12. Ko JH, Jung BG, Park YS, Lee BJ (2011) Inhibitory effects of interferon-gamma plasmid DNA on DMBA-TPA induced mouse skin carcinogenesis. Cancer Gene Ther 18:646–654

  13. Lange S, Gögel S, Leung K-Y, Vernay B, Nicholas AP, Causey CP, Thompson PR, Greene NDE,Ferretti P (2011) Protein deiminases: new players in the developmentally regulated loss of neural regenerative ability. Dev Biol 355:205–214

  14. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408

  15. McElwee JL, Mohanan S, Horibata S, Sams KL, Anguish LJ, McLean D, Cvitas I, Wakshlag JJ, Coonrod SA (2014) PAD2 overexpression in transgenic mice promotes spontaneous skin neoplasia. Cancer Res 74:6306–6317

  16. Nelson MA, Futscher BW, Kinsella T, Wymer J, Bowden GT (1992) Detection of mutant ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors. Proc Natl Acad Sci U S A 89:6398–6402

  17. Pena JC, Rudin CM, Thompson CB (1998) A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res 58:2111–2116

  18. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25:1106–1118

  19. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 10:545–553

  20. Wang D, Russell JL, Johnson DG (2000) E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. Mol Cell Biol 20:3417–3424

  21. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, Luo Y, Levitt B, Glogowska M, Chandra P, Kulik L, Robinson WH, Arend WP, Thompson PR, Holers VM (2011) N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol 186:4396–4404

  22. Woodworth CD, Michael E, Smith L, Vijayachandra K, Glick A, Hennings H, Yuspa SH (2004) Strain-dependent differences in malignant conversion of mouse skin tumors is an inherent property of the epidermal keratinocyte. Carcinogenesis 25:1771–1778

  23. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51

Download references

Author information

Correspondence to Scott A. Coonrod.

Electronic supplementary material

Supplementary Fig. 1
figure6

DMBA-TPA treated WT and PAD2 overexpressing (PAD2OE) tumor samples carry an activating mutation in codon 61 of Hras. Xbal digestion product indicates presence of activating mutation in tested (n = 3) WT and PAD2OE tumors. Untreated tissue from WT and PAD2OE lines did not contain the mutation. (GIF 46 kb)

Supplementary Fig. 2
figure7

High-magnification images showing range of histotypes seen in WT and PAD2OE tumors following DMBA-TPA treatment. Representative images of hyperplasia (a), dysplasia (b), and anaplasia (c). (GIF 205 kb)

High resolution image (TIFF 3625 kb)

High resolution image (TIFF 11567 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mohanan, S., Horibata, S., Anguish, L.J. et al. PAD2 overexpression in transgenic mice augments malignancy and tumor-associated inflammation in chemically initiated skin tumors. Cell Tissue Res 370, 275–283 (2017). https://doi.org/10.1007/s00441-017-2669-x

Download citation

Keywords

  • DMBA-TPA carcinogenesis model
  • Peptidylarginine deiminase 2 (PAD2)
  • PAD2 overexpression
  • Tumor associated inflammation
  • Squamous cell carcinoma